openPR Logo
Press release

Little Children Are Being Labeled For Profit

02-29-2016 11:52 AM CET | Health & Medicine

Press release from: Citizens Commission on Human Rights

Vancouver- February 27, 2016 - A video documentary produced by the Citizens Commission on Human Rights International called “Dead Wrong” exposes how devastating—and deadly—psychiatric drugs can be for children and families.

Behind the grim statistics of deaths, suicides, birth defects and serious adverse reactions is the human face of this global drugging epidemic—the personal stories of loss and courage of those who paid the real price.

Psychiatrists claim their drugs are safe for children? Once you hear what eight brave mothers, their families, health experts, drug counselors and doctors have to say instead, you will come away convinced of one thing. Psychiatrists are Dead Wrong.

20 million children are labeled with "mental disorders" that are based solely on a checklist of behaviors. There are no brain scans, x-rays, genetic or blood tests that can prove they are mentally ill, yet these children are prescribed dangerous and life-threatening psychiatric drugs. Child drugging is a $4.8 billion-a-year industry.

The psychiatric/pharmaceutical industry spends billions of dollars a year in order to convince the public, legislators and the press that psychiatric disorders such as Bi-Polar Disorder, Depression, Attention Deficit Disorder (ADD/ADHD), Post Traumatic Stress Disorder, etc., are medical diseases on par with verifiable medical conditions such as cancer, diabetes and heart disease. This is simply a way to maintain their hold on a $84 billion dollar-a-year psychiatric drug industry that is based on marketing and not science.

Brian Beaumont, president of the Vancouver chapter of the Citizens Commission on Human Rights (CCHR) said, “Unlike real medical disease, there are no scientific tests to verify the medical existence of any psychiatric disorder. Despite decades of trying to prove mental disorders are biological brain conditions, due to chemical imbalances or genetic factors, psychiatry has failed to prove even one of their hundreds of so-called mental disorders is due to a faulty or “chemically imbalanced” brain”.

The Citizens Commission on Human Rights was established by the Church of Scientology to investigate and expose psychiatric violations of human rights.

401 West Hastings Street
Vancouver, British Columbia
V6B 1L5

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Little Children Are Being Labeled For Profit here

News-ID: 324765 • Views: 1073

More Releases for Disorder

Anti-Depressant Drugs Market to 2027 - Global Analysis and Forecasts By Depressi …
Anti-depressant drugs is a class of medications which is used to treat major depressive disorder, some anxiety disorders, some chronic pain conditions, and to help manage some addictions. Anti-depressant drugs also reduce symptoms of depressive disorders by correcting chemical imbalances of neurotransmitters in the brain. Chemical imbalances may be responsible for changes in mood and behavior. Anti-depressant drugs market is anticipated to grow in the forecast period owing to driving factors
Antidepressant Drugs Market Report 2018: Segmentation by Depressive Disorder (Ma …
Global Antidepressant Drugs market research report provides company profile for Alkermes Plc, Allergan Plc, Bristol Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck, Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd. and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms
Autism Spectrum Disorder (ASD) Treatment Market Report 2018: Segmentation by Aut …
Global Autism Spectrum Disorder (ASD) Treatment market research report provides company profile for Roche Pharmaceuticals, Autism Treatment Plus, Fraser, Retrophin, Inc., Autism Services Inc., Pfizer Inc., SynapDx, Behavior Analysis, Inc., Autism Therapeutics, Curemark LLC and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate,
Speech Therapy Service Market Report 2018: Segmentation by Product (Speech Disor …
Global Speech Therapy Service market research report provides company profile for Benchmark Therapies, Talk Speech, Language Therapy, Speech Plus, Smart Speech Therapy, Therapy Solutions, Glenda Browne Speech Pathology and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018
Somatostatin Receptor Market For Hormonal Disorder, Oncology, Metabolic Disorder
MarketResearchReports.Biz adds “Global Somatostatin Receptor Market Share, Size, Trends and Forecast Market Research Report” reports to its database. This report provides a strategic analysis of the Somatostatin Receptor and the growth estimates for the forecasted period. This report studies the Somatostatin Receptor Type 2 market status and outlook of global and United States, from angles of players, regions, product types and end industries; this report analyzes the top players in global
Thyroid Gland Disorder Treatment Market: Increasing incidence of Autoimmune Dise …
The global market for thyroid gland disorders features a consolidated vendor landscape with a handful of companies accounting for a major chunk of the global market, observes Transparency Market Research in a recent report. In 2016, the thyroid gland disorders treatment market was dominated by Merck KGaA and AbbVie, Inc., which collectively accounted for more than half of the market. It has been observed that despite the large pool of